<?xml version="1.0" encoding="ASCII"?>
<biogps><data><item key="owner">ArrayExpress Uploader</item><item key="ownerprofile_id">arrayexpress_sid</item><item key="species">human</item><item key="factors"><item><item key="GSM618185"><item key="ESTROGEN-RECEPTOR STATUS">ER-positive</item><item key="CELL LINE">MCF7</item><item key="GENOTYPE/VARIATION">miR-210 overexpression</item></item></item><item><item key="GSM618185"><item key="ESTROGEN-RECEPTOR STATUS">ER-positive</item><item key="CELL LINE">MCF7</item><item key="GENOTYPE/VARIATION">miR-210 overexpression</item></item></item><item><item key="GSM618187"><item key="ESTROGEN-RECEPTOR STATUS">ER-positive</item><item key="CELL LINE">MCF7</item><item key="GENOTYPE/VARIATION">control (for miR-210 overexpression)</item></item></item><item><item key="GSM618187"><item key="ESTROGEN-RECEPTOR STATUS">ER-positive</item><item key="CELL LINE">MCF7</item><item key="GENOTYPE/VARIATION">control (for miR-210 overexpression)</item></item></item><item><item key="GSM618189"><item key="ESTROGEN-RECEPTOR STATUS">ER-negative</item><item key="CELL LINE">MDA-MB-231</item><item key="GENOTYPE/VARIATION">miR-210 repression</item></item></item><item><item key="GSM618189"><item key="ESTROGEN-RECEPTOR STATUS">ER-negative</item><item key="CELL LINE">MDA-MB-231</item><item key="GENOTYPE/VARIATION">miR-210 repression</item></item></item><item><item key="GSM61819"><item key="ESTROGEN-RECEPTOR STATUS">ER-negative</item><item key="CELL LINE">MDA-MB-231</item><item key="GENOTYPE/VARIATION">control (for miR-210 repression)</item></item></item><item><item key="GSM61819"><item key="ESTROGEN-RECEPTOR STATUS">ER-negative</item><item key="CELL LINE">MDA-MB-231</item><item key="GENOTYPE/VARIATION">control (for miR-210 repression)</item></item></item></item><item key="id">3859</item><item key="pop_total">0</item><item key="platform">4</item><item key="summary_wrapped">As miR-210 expression is correlated to poor prognosis both in estrogen-positive and in estrogen-negative breast cancer (BC) patients, we...</item><item key="geo_gse_id">E-GEOD-25162</item><item key="owner_profile">/profile/8773/arrayexpressuploader</item><item key="factor_count">3</item><item key="sample_count">8</item><item key="tags"><item>breast</item><item>breast cancer</item><item>cancer</item><item>cell</item><item>epithelial cell</item><item>estrogen</item><item>line</item></item><item key="lastmodified">Dec.12, 2014</item><item key="is_default">False</item><item key="geo_id_plat">E-GEOD-25162_A-AFFY-44</item><item key="slug">functional-analyses-of-mir-210-involvement-in-the</item><item key="geo_gds_id"/><item key="name">Functional analyses of miR-210 involvement in the aggressive phenotype of high grade breast tumors</item><item key="created">Sep.15, 2014</item><item key="summary">As miR-210 expression is correlated to poor prognosis both in estrogen-positive and in estrogen-negative breast cancer (BC) patients, we aimed to investigate the biological processes regulated by miR-210 and which may elucidate its function in the aggressive phenotype of high grade breast cancer. We performed in silico functional analyses of the genes deregulated upon miR-210 overexpression in MCF7 BC cell line and upon miR-210 repression in MDA-MB-231 BC cell line using lentiviral transduction. Gene expression profiling analysis of these cells revealed the deregulation of genes involved in several biological pathways including cell adhesion, extracellular structure organization, epithelial cell proliferation, cell division, cell cycle and immune response. MCF-7 cells overexpressing miR-210 (or control) and MDA-MB-231 cells in which miR-210 (or control) is repressed were used for RNA extraction and hybridization on Affymetrix microarrays.</item><item key="source">http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-25162</item><item key="sample_source">http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-25162/samples/</item></data></biogps>
